This Pharma Stock Is Rising. The Weight-Loss Drugs Race Has Widened Beyond Lilly, Novo.
Viking says an early-stage study of its obesity pill VK2735 showed adults on the highest dosage lost 8.2% of their body weight in four weeks.
Viking rises after 'competitive' efficacy, safety data from oral weight-loss drug
(Reuters) -Viking Therapeutics shares climbed 9% on Monday after the drug developer's oral obesity treatment helped reduce body weight with mild side effects in a small trial, data that analysts said compared favorably to some rivals in development.
Lilly cuts outlook on surprising weight-loss drug disappointment
Eli Lilly and Co. lowered its full-year guidance Wednesday on lackluster sales of its blockbuster weight-loss drug, a shocking miss for a drugmaker that had been going from strength to strength on insatiable demand for these drugs.
Competition will make weight-loss drugs better, cheaper and bigger
A mong the many newcomers to the business of weight-loss drugs is Hims & Hers, an American e-pharmacy better known for hawking remedies for erectile dysfunction and hair loss. Since May it has offered its own version of Wegovy,
Viking Therapeutics stock jumps after ‘great’ trial of weight-loss drug
Viking Therapeutics stock rose in early trade on Monday as the company showed its oral weight-loss drug in clinical trials was successful.
This Pharma Stock Is Soaring 21%. The Weight-Loss Drugs Race Has Widened Beyond Lilly, Novo.
Viking said that an early-stage study of its obesity pill VK2735 showed adults on the highest dosage lost 8.2% of their body weight in four weeks.
Viking Therapeutics Stock Swings Wildly After Weight-Loss Drug Data
Viking Therapeutics stock is volatile Monday after the pharma company released positive data for its weight-loss drug. Here's what you need to know.
STAT3d
Pharmalittle: We’re reading about a weight loss pill, the FDA warning a compounder, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, ...
Americans seeking Eli Lilly and Novo Nordisk’s weight-loss drugs turn to compounded market
Analysts have struggled to estimate the size of the compounded market for weight-loss drugs because their sale is not ...
Seeking Alpha2d
How does Viking's weight loss med compare to ones from Novo, Eli Lilly?
It also has another pill, amycretin ... said it expects CagriSema and amycretin to achieve better weight loss results than Wegovy. Lilly is also developing the GIP/GLP-1/glucagon receptor ...
The Australian Financial Review1mon
Weight loss wars: a century on, the battle heats up
With the most potent weight-loss shot and a pipeline of 11 experimental treatments, including what is widely expected to be the first approved small molecule GLP-1 pill, Eli Lilly stands to be ...
Nasdaq1mon
Eli Lilly (NYSE:LLY) Eyes Broader Market for Weight-Loss Drugs
So far, the trials for Eli Lilly’s weekly anti-obesity injection, Zepbound, as well as its experimental weight-loss pill, orforglipron, have included patients with a BMI of 30 or higher ...
Wall Street Lunch: Viking Weight-Loss Pill Data Is Striking
VK2735 is a dual GLP-1/GIP receptor agonist similar to Eli Lilly's (LLY) blockbuster weight loss drug Zepbound, ...
The end of a shortage of popular weight-loss drugs may mean many people lose access to them
Some patients fear that they’ll lose access to tirzepatide because the US Food and Drug Administration determined that a shortage of the brand-name drug has ended – which means compounding of the ...